Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M
Ligand acquires partial royalty rights to epilepsy candidate: Ligand said Wednesday that it’s paying $30 million upfront to Ovid Therapeutics as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
